<DOC>
	<DOC>NCT01239758</DOC>
	<brief_summary>To evaluate the long-term safety and tolerability of ACE-031 administration in subjects with Duchenne muscular dystrophy (DMD) who participated in Study A031-03. [Note: This study was terminated based on preliminary safety data. Pending further analysis of safety data and discussion with health authorities, a new ACE-031 trial will be planned.]</brief_summary>
	<brief_title>Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
	<criteria>Completion of participation in Study A03103 and Investigator approval Continuation of corticosteroid therapy at the same absolute dose and schedule as on Study A03103 Participation in any other therapeutic clinical trial Plans to have surgery during the course of the study</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>